Breaks Categories: News

TuesdayFeb 17, 2026 2:40 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway 

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and…

Continue Reading

TuesdayFeb 17, 2026 10:45 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Announces Governance and Capital Structure Initiatives to Advance Institutional Readiness

Earth Science Tech (OTC: ETST) announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. Building on approximately $3.3 million in net income for fiscal 2025 and anticipated $1.4 million in cost savings in fiscal 2026, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation, introduce advisory shareholder votes on executive compensation and Series B Preferred Stock retirement, rationalize its capital structure and reduce executive and board compensation, as management positions the company for disciplined growth and improved…

Continue Reading

TuesdayFeb 17, 2026 10:35 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages Semple, Marchal & Cooper as New PCAOB Auditor

Earth Science Tech (OTC: ETST) announced it has engaged Semple, Marchal & Cooper LLP as its new independent Public Company Accounting Oversight Board auditor, citing the need to strengthen its financial governance framework as operations expand across pharmacy compounding, telemedicine and real estate. The board determined that the firm’s broader resources and multidisciplinary expertise align with the company’s growing operational complexity, supporting enhanced auditing efficiencies and oversight as ETST continues scaling its diversified health and wellness portfolio. To view the full press release, visit https://ibn.fm/hEaGE About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company,…

Continue Reading

TuesdayFeb 17, 2026 10:25 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal Q3 2026 Revenue Up 14% and Net Income Up 341%

Earth Science Tech (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and…

Continue Reading

TuesdayFeb 17, 2026 10:15 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers. To view the full press release, visit https://ibn.fm/lcSDZ About…

Continue Reading

TuesdayFeb 17, 2026 10:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company’s vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company’s profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform. To view the full press release, visit https://ibn.fm/iSd01 About Earth Science Tech, Inc. Earth Science Tech, Inc.…

Continue Reading

TuesdayFeb 17, 2026 9:30 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models

Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that Telomir-Zn reduces labile redox-active iron while increasing zinc availability, targeting the elevated iron levels and oxidative stress observed in many triple-negative breast cancer tumors. To view the full press release, visit https://ibn.fm/CHKT9 About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing…

Continue Reading

TuesdayFeb 17, 2026 9:26 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products 

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio.  To view the full press release, visit https://ibn.fm/2YOl8  About Nutriband Inc.  We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch…

Continue Reading

ThursdayFeb 12, 2026 10:50 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line data from the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma expected in the second half of 2026, with an interim analysis approaching in the second quarter and 66 of 80 patients enrolled as of Feb. 10. The letter also reviewed positive Phase 2a data for SGX945 (dusquetide) in Behçet’s Disease published in Rheumatology (Oxford), encouraging Phase 2a psoriasis results for SGX302, ongoing strategic evaluations including partnership and M&A opportunities, and the company’s…

Continue Reading

ThursdayFeb 12, 2026 10:39 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a proprietary TGF-β antisense therapeutic platform, with allowed patent claims in Australia covering OT-101 (SEQ ID NO:9) for the treatment of Parkinson’s Disease, including associated sleep-related symptoms, and granted utility model patents in China and Germany for an intracranial continuous infusion delivery device. The company stated the expanded protection spans therapeutic use claims, CNS delivery methods, device-enabled administration and broader oncology and neurology applications, forming an integrated commercialization platform intended to strengthen long-term defensibility, support strategic partnerships and enhance shareholder value, with additional data presentations planned…

Continue Reading